Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036813 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
NCT03036813 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 449 participants.
The verdict
NCT03036813, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
Study Summary
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
Interventions
- OTHER Placebo
- DRUG voxelotor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03036813
The ClinicalTrials.gov registry entry for NCT03036813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03036813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03036813 about?
NCT03036813 is a clinical study titled "Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)". A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
What is the current status of trial NCT03036813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2016-12. Estimated completion is 2019-10-08.
What interventions are being tested in trial NCT03036813?
The interventions under investigation include: Placebo (OTHER), voxelotor (DRUG).
Who is sponsoring clinical trial NCT03036813?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.